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245 actinomycin D, and the other that is telomere-bound where it functions in maintaining telomere 246 stability independent of AR transcriptional activity and is resistant to actinomycin D.
247
Notably, actinomycin D inhibits transcription as a result of its ability to intercalate into 248 DNA; however, owing to differences in histone modifications and compactness of nucleosomes, 249 actinomycin D intercalates and disrupts DNA-protein interactions at least three times more 250 efficiently in euchromatin than in heterochromatin (35-37). Telomeric and subtelomeric 251 chromatin is considered heterochromatin as it is enriched in epigenetic marks that are 252 characteristic of heterochromatin, such as H3K9me3, H4K20me3, and hypoacetylated H3 and 253 H4 (38). The heterochromatin state of telomeres is also evident from the presence of SIRT6, a 254 histone deacetylase that promotes transcriptional silencing, and heterochromatin protein HP1-γ 255 required for telomere cohesion (39, 40).
256
Thus, we hypothesized that actinomycin D might disrupt euchromatin-associated AR 257 more efficiently than telomere-associated AR. We first tested this hypothesis using LNCaP cells 258 that express only full-length AR. We treated cells with actinomycin D and then prepared them 259 for immunolabeling of AR and TIN2. Actinomycin D treatment indeed decreased the amount of 260 nuclear AR, but had no effect on TIN2 protein (Fig. 2A) . Most notably, most of the cytoskeleton 261 buffer-resistant AR in actinomycin D-treated cells was colocalized with TIN2 ( Fig 
265
We further validated the association of actinomycin D-resistant AR with telomeres by 266 analyzing AR-chromatin immunoprecipitate (AR-ChIP) for the presence of telomere DNA, using 267 PCR primers that amplify sequence extending from the sub-telomere region of chromosome 268 17p into its telomere (17p-Tel) (Fig. 2C) . As expected, AR-ChIP prepared from untreated 269 LNCaP cells (Fig. 2D, vehicle) contains androgen response elements (AREs) of AR-target 12 270 genes PSA and NDRG1. Notably, AR-ChIP also contains telomere DNA of chromosome 17p 271 (Fig. 2D, vehicle) , consistent with our previous finding of telomere repeat DNA in AR-ChIP of 272 LNCaP cells (7).
273
By contrast, AR-ChIP prepared from actinomycin D-treated cells (Fig. 2D , actinomycin 274 D) had a decreased presence of AREs; this is presumably due to the ability of actinomycin D to 275 disrupt AR binding to euchromatin and inhibit transcription. Notably, however, actinomycin D 276 had no effect on the presence of 17p-telomere DNA in AR-ChIP (Fig. 2D) , affirming the 277 association of actinomycin D-resistant AR with telomeres.
278
We next used actinomycin D to address the question whether the AR splice variant AR-279 V7 in 22Rv1 cells is associated with telomeres and whether AR-V7 plays a role in telomere 280 stability. Dual immunofluorescence labeling of 22Rv1 cells was carried out using TIN2 antibody 281 and either antibody AR-441 that recognizes both full-length AR and variant AR-V7, or antibody 282 specific to AR-V7 (Fig. 2E) . Colocalization of the N-terminal domain of AR (using antibody AR-283 441) with TIN2 at telomeres was evident in vehicle-treated cells, but AR-V7 was rarely seen at 284 telomeres (vehicle panels in Figs. 2E, 2F); this suggests that it is predominantly full-length AR 285 associated with telomeres. Treatment of 22Rv1 cells with actinomycin D and subsequent 286 washing with cytoskeleton buffer plus 0.5% Triton X-100 allowed for a large decrease in nuclear 287 AR staining with no change in telomere TIN2 (Fig. 2E , compare vehicle vs. Act D). The 288 predominant colocalization of AR-441 with TIN2, and relative lack of colocalization of AR-V7 289 with TIN2, were evident whether or not cells were pre-treated with actinomycin D (Fig. 2E ), but 290 identification and quantitation of colocalized foci was facilitated by the removal of soluble and 291 loosely bound AR (Fig. 2F) .
292
The apparent presence of a small subset of AR-V7 at telomeres in 22Rv1 cells (Fig. 2F) 293 suggests a possible role in telomere stability, perhaps via heterodimerization with full-length AR 294 (41). To address this question, we tested the effect of knockdown of f-AR and/or AR-V7 on 15 345 and S3) and increased cell death (Fig. 5E) 
360
The AR is a well-characterized transcription factor that regulates the expression of 361 many genes (19), including many that play a role in DNA repair (44, 45). In those studies, the 362 growth inhibitory effect of ionizing radiation-induced genome-wide DNA damage was enhanced 363 by AR inactivation, and this enhancement was inferred to be the result of decreased expression 364 of DNA repair genes (44, 45). By contrast, our data indicate that AR antagonist induces 365 telomere DNA damage independent of an effect on AR transcriptional activity (7). In addition, 366 AR inactivation does not cause genome-wide DNA damage (6, 44), but by inducing telomere 367 DNA damage and activating a telomere DDR, an opportunity to inhibit DNA repair is created, 368 the consequence of which is to promote cell death, as genome integrity is required for survival. 371 This feature fits the criterion for synthetic lethality (46), although incomplete tumor elimination in 372 our study suggests the need to target additional pathways or other components of the telomere 373 DDR and repair pathway.
374
There is growing interest in combined targeting of AR and DNA repair in CRPC, using 375 ENZ or androgen ablation plus an inhibitor of poly (ADP-ribose) polymerase (PARP) (47, 48) or 376 an inhibitor of both Chk1 and Chk2 (49). Notably, these other studies focus on inhibiting 377 genome-wide DNA repair, whereas our own studies focus on inhibiting the repair of telomere 378 DNA damage. Cesare et al (50) have reported that the telomere DDR is functionally distinct 379 from the genomic DDR.
380
Many cell types, including prostate cancer, use AR to modulate specific gene 381 expression, but prostate cancer cells uniquely require AR to regulate cell proliferation and cell 382 survival. Similarly, most cells do not need AR for telomere stability, but our studies have shown 383 a critical role of AR in telomere stability in prostate cancer cells (6). Our data indicate that this 384 role is mediated by a subset of AR associated with telomeres ((6) and this study), although it is
385 not yet clear how AR is tethered to telomeres. Immunofluorescent colocalization of AR with 386 telomere protein TIN2 was seen clearly after pretreating cells with actinomycin D and washing 387 with cytoskeleton buffer to extract soluble nuclear AR (Fig. 2) . Thus, actinomycin D treatment 388 may be a useful tool for studying telomere-associated AR.
389
In summary, we have demonstrated that CRPC 22Rv1 tumor growth is resistant to AR 390 antagonist or ATMi as monotherapies, but is significantly inhibited by combined treatment.
391 CRPC cells that express both full-length AR and splice variant AR-V7 and are not growth 392 inhibited by AR antagonist are inferred to depend on, and are said to be driven by AR-V7; but, 393 ironically, it is their expression of full-length AR that makes them sensitive to growth inhibition by 394 combined treatment with ENZ plus ATMi. For each treatment group, the median and 95% confidence interval for time to tumor 655 volume ~2000 mm 3 and log rank p-values were computed using the SAS procedure PROC 656 LOGISTIC. Time to sacrifice was not adjusted for differences in tumor size at the start of 657 treatment.
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